Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors - PubMed (original) (raw)

• PMID: 6481426
• DOI: 10.1007/BF00177899

Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors

D J Stewart et al. J Neurooncol. 1984.

Abstract

VP-16 100 mg/m2 was given intravenously to 10 patients undergoing surgical resection of intracerebral tumors, and the drug was assayed in resected tumor using high pressure liquid chromatography. VP-16 concentrations varied from undetectable (less than .1 microgram/g) to 5.9 micrograms/g (mean, 1.4 microgram/g). VP-16 concentrations in tumors were lower than concurrent plasma concentrations. In addition, intracerebral tumors had a lower concentration of VP-16 than did extracerebral tumors (mean VP-16 concentration, 3.9 micrograms/g) from 7 patients receiving VP-16 50-100 mg/m2 intravenously. Plasma pharmacokinetics of VP-16 were different in our patients with intracerebral tumors than in previously studied patients with extracerebral tumors and it is unclear what role this may played in variability of tumor VP-16 concentrations. VP-16 concentrations were similar in glioblastomas and brain metastases. Specimens from patients with small cell undifferentiated carcinoma of the lung had the highest VP-16 concentrations. A patient who had both viable and necrotic tumor resected during an occipital lobectomy had a higher drug concentration in the necrotic than in the viable area of tumor. In addition, VP-16 concentration decreased as a function of distance into brain from the tumor. Based on our data, VP-16 might be expected to have less activity against intracerebral than against extracerebral human tumors.

PubMed Disclaimer

Similar articles

• Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
  Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN. Hande KR, et al. Cancer Res. 1984 Jan;44(1):379-82. Cancer Res. 1984. PMID: 6690051
• Clinical pharmacology of intracarotid etoposide.
  Savaraj N, Feun LG, Lu K, Wallace S, Fields WS, Loo TL. Savaraj N, et al. Cancer Chemother Pharmacol. 1986;16(3):292-4. doi: 10.1007/BF00293995. Cancer Chemother Pharmacol. 1986. PMID: 3698170
• Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
  Stewart DJ, Nundy D, Maroun JA, Tetreault L, Prior J. Stewart DJ, et al. Cancer Treat Rep. 1985 Mar;69(3):269-73. Cancer Treat Rep. 1985. PMID: 3884152 Clinical Trial.
• Podophyllotoxin derivative VP 16-213.
  Arnold AM. Arnold AM. Cancer Chemother Pharmacol. 1979;3(2):71-80. doi: 10.1007/BF00254976. Cancer Chemother Pharmacol. 1979. PMID: 389478 Review.
• Etoposide (VP-16-213). Current status of an active anticancer drug.
  O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. O'Dwyer PJ, et al. N Engl J Med. 1985 Mar 14;312(11):692-700. doi: 10.1056/NEJM198503143121106. N Engl J Med. 1985. PMID: 2983208 Review. No abstract available.

Cited by

• Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.
  Henwood JM, Brogden RN. Henwood JM, et al. Drugs. 1990 Mar;39(3):438-90. doi: 10.2165/00003495-199039030-00008. Drugs. 1990. PMID: 2184009 Review. No abstract available.
• Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy.
  Mehta A, Awah CU, Sonabend AM. Mehta A, et al. Front Neurol. 2018 Jun 20;9:459. doi: 10.3389/fneur.2018.00459. eCollection 2018. Front Neurol. 2018. PMID: 29988316 Free PMC article. Review.
• A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.
  Stewart DJ. Stewart DJ. J Neurooncol. 1994;20(2):121-39. doi: 10.1007/BF01052723. J Neurooncol. 1994. PMID: 7807190 Review.
• Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.
  Fulton D, Urtasun R, Forsyth P. Fulton D, et al. J Neurooncol. 1996 Feb;27(2):149-55. doi: 10.1007/BF00177478. J Neurooncol. 1996. PMID: 8699237 Clinical Trial.
• Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
  Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE. Miller TW, et al. J Neurooncol. 2019 Sep;144(3):563-572. doi: 10.1007/s11060-019-03258-0. Epub 2019 Aug 9. J Neurooncol. 2019. PMID: 31399936 Free PMC article. Clinical Trial.

References

1. 1. Cancer Res. 1979 Oct;39(10):4119-22 - PubMed
2. 1. Cancer Chemother Pharmacol. 1979;3(2):71-80 - PubMed
3. 1. Cancer. 1974 Feb;33(2):460-7 - PubMed
4. 1. J Neurooncol. 1983;1(1):15-9 - PubMed
5. 1. Hum Pathol. 1975 Sep;6(5):611-21 - PubMed

MeSH terms

Substances